• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Antibacterial Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019 Product Image

Antibacterial Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019

  • ID: 2776212
  • March 2014
  • Region: Global
  • 110 Pages
  • Transparency Market Research

FEATURED COMPANIES

  • AstraZeneca plc
  • Bayer AG
  • Eli Lilly and Company
  • Forest Laboratories, Inc.
  • GlaxoSmithKline plc
  • Johnson & Johnson
  • MORE

'Antibacterial Drugs Market (By Class - Aminoglycosides, B-Lactams, Tetracyclines, Sulfonamides, Quinolones/ Fluoroquinolones, Macrolides and Phenicols, and Pipeline Analysis) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019'

This report on antibacterial drugs market studies the current as well as future prospects of the market globally. The market for antibacterial drugs is segmented on the basis of major classes of drugs, namely, aminoglycosides, B-lactams, tetracyclines, sulfonamides, quinolones/fluoroquinolones, macrolides and phenicols. The market for these classes has been extensively analyzed on the basis of the leading drug launch, expiry, efficacy, sales revenue and geographic presence.

The market size and forecast in terms of USD million for each of these classes has been provided for the period 2011 to 2019, considering 2012 as the base year. The report on antibacterial drugs market also provides % compounded annual growth rate (CAGR) for each market segment for the forecast period 2013 to 2019.

Geographically, the antibacterial drugs market has been categorized into four regions namely, North America, Europe, Asia-Pacific, READ MORE >

FEATURED COMPANIES

  • AstraZeneca plc
  • Bayer AG
  • Eli Lilly and Company
  • Forest Laboratories, Inc.
  • GlaxoSmithKline plc
  • Johnson & Johnson
  • MORE

Chapter 1 Preface
1.1 Report Description
1.2 Market Segmentation
1.3 Research Methodology
1.3.1 Sources
1.3.1.1 Secondary Research
1.3.1.2 Primary Research

Chapter 2 Executive Summary

Chapter 3 Market Overview
3.1 Introduction to Antibacterial Drugs
3.2 Market Trends and Future Outlook
3.2.1 Impact of generics
3.3 Market Drivers
3.3.1 Global increasing prevalence of a large number of infectious diseases
3.3.2 Rising demand for effective and affordable antibacterial drugs from emerging economies
3.3.3 Aging population
3.4 Market Restraints
3.4.1 Weak pipeline of novel antibacterial drugs
3.4.2 Patent expirations
3.4.3 Rising number of generic drugs in various antibacterial drug classes
3.4.4 Increasing number of multi-drug resistant bacterial strains
3.5 Market Opportunities
3.5.1 Product differentiation through technological innovation, use of monoclonal antibodies (mAbs), combination products, new formulations and indications
3.5.2 Product development through partnerships
3.6 Porter’s Five Forces Analysis for the Global Antibacterial Drugs Market
3.6.1 Bargaining power of suppliers
3.6.2 Bargaining power of buyers
3.6.3 Threat of substitutes
3.6.4 Threat of new entrants
3.6.5 Competitive rivalry
3.7 Market Attractiveness Analysis: Global Antibacterial Drugs Market, by Geography

Chapter 4 Global Antibacterial Drugs Market Revenue, by Class, 2011 - 2019 (USD Million)
4.1 Overview
4.1.1 Global Antibacterial Drugs Market Revenue, by Class, 2011 – 2019 (USD Million)
4.1.2 Comparative Analysis: Global Antibacterial Drugs Market Revenue, by Class, 2012 & 2019 (Value %)
4.2 Aminoglycosides
4.2.1 Global Aminoglycosides Market Revenue, 2011 – 2019 (USD Million)
4.3 B-Lactams
4.3.1 Global B-Lactams Market Revenue, 2011 – 2019 (USD Million)
4.3.2 Penicillins
4.3.3 Carbapenems
4.3.4 Cephalosporins
4.4 Tetracyclines
4.4.1 Global Tetracyclines Market Revenue, 2011 – 2019 (USD Million)
4.5 Sulfonamides
4.5.1 Global Sulfonamides Market Revenue, 2011 – 2019 (USD Million)
4.6 Quinolones/Fluoroquinolones
4.6.1 Global Quinolones/Fluoroquinolones Market Revenue, 2011 – 2019 (USD Million)
4.7 Macrolides
4.7.1 Global Macrolides Market Revenue, 2011 – 2019 (USD Million)
4.8 Phenicols
4.8.1 Global Phenicols Market Revenue, 2011 – 2019 (USD Million)

Chapter 5 Global Antibacterial Drugs Market Revenue, Pipeline Analysis (USD Million)
5.1 Overview
5.2 Delafloxacin (RX-3341)
5.2.1 Global Delafloxacin Market, 2015 – 2019 (USD Million)
5.3 Surotomycin (CB-315)
5.3.1 Global Surotomycin Market, 2016 – 2019 (USD Million)
5.4 Tedizolid (TR-701)
5.4.1 Global Tedizolid Market, 2015 – 2019 (USD Million)
5.5 Ceftolozane/Tazobactam
5.5.1 Global Ceftolozane/Tazobactam Market, 2015 – 2019 (USD Million)
5.6 Dalvance (dalbavancin)
5.6.1 Global Dalvance (dalbavancin) Market, 2015 – 2019 (USD Million)
5.7 Eravacycline (TP-434)
5.7.1 Global Eravacycline Market, 2016 – 2019 (USD Million)
5.8 Delamanid (OPC-67683)
5.8.1 Global Delamanid Market, 2017 – 2019 (USD Million)
5.9 CAZ AVI
5.9.1 Global CAZ AVI Market, 2015 – 2019 (USD Million)
5.10 Solithromycin (CEM-101)
5.10.1 Global Solithromycin Market, 2016 – 2019 (USD Million)
5.11 MK-3415A
5.11.1 Global MK-3415A Market, 2016 – 2019 (USD Million)
5.12 Oritavancin
5.12.1 Global Oritavancin Market, 2015 – 2019 (USD Million)

Chapter 6 Global Antibacterial Drugs Market Revenue, by Geography, 2011 - 2019 (USD Million)
6.1 Overview
6.1.1 Global Antibacterial Drugs Market Revenue, by Geography, 2011 – 2019 (USD Million)
6.1.2 Comparative Analysis: Global Antibacterial Drugs Market Revenue, by Geography, 2012 & 2019 (Value %)
6.2 North America
6.2.1 North America Antibacterial Drugs Market Revenue, 2011 - 2019 (USD Million)
6.3 Europe
6.3.1 Europe Antibacterial Drugs Market Revenue, 2011 - 2019 (USD Million)
6.4 Asia-Pacific
6.4.1 Asia-Pacific Antibacterial Drugs Market Revenue, 2011 - 2019 (USD Million)
6.5 Rest of the World (RoW)
6.5.1 RoW Antibacterial Drugs Market Revenue, 2011 - 2019 (USD Million)

Chapter 7 Competitive Landscape
7.1 Market Share Analysis: Global Antibacterial Drugs Market (2012)

Chapter 8 Recommendations
8.1 Development of combination products
8.2 Generic pharmaceuticals: Targeting emerging markets such as India, China, Brazil, Mexico and South Africa
8.3 Strategic collaborations with small biotechnology and research companies

Chapter 9 Company Profiles
9.1 AstraZeneca plc
9.1.1 Company Overview
9.1.2 Financial Overview
9.1.3 Product Portfolio
9.1.4 Business Strategies
9.1.5 Recent Developments
9.2 Bayer AG
9.2.1 Company Overview
9.2.2 Financial Overview
9.2.3 Product Portfolio
9.2.4 Business Strategies
9.2.5 Recent Developments
9.3 Bristol-Myers Squibb Company
9.3.1 Company Overview
9.3.2 Financial Overview
9.3.3 Product Portfolio
9.3.4 Business Strategies
9.3.5 Recent Developments
9.4 Eli Lilly and Company
9.4.1 Company Overview
9.4.2 Financial Overview
9.4.3 Product Portfolio
9.4.4 Business Strategies
9.4.5 Recent Developments
9.5 Forest Laboratories, Inc.
9.5.1 Company Overview
9.5.2 Financial Overview
9.5.3 Product Portfolio
9.5.4 Business Strategies
9.5.5 Recent Developments
9.6 GlaxoSmithKline plc
9.6.1 Company Overview
9.6.2 Financial Overview
9.6.3 Product Portfolio
9.6.4 Business Strategies
9.6.5 Recent Developments
9.7 Johnson & Johnson
9.7.1 Company Overview
9.7.2 Financial Overview
9.7.3 Product Portfolio
9.7.4 Business Strategies
9.7.5 Recent Developments
9.8 Merck & Co., Inc.
9.8.1 Company Overview
9.8.2 Financial Overview
9.8.3 Product Portfolio
9.8.4 Business Strategies
9.8.5 Recent Developments
9.9 Novartis AG
9.9.1 Company Overview
9.9.2 Financial Overview
9.9.3 Product Portfolio
9.9.4 Business Strategies
9.9.5 Recent Developments
9.10 Pfizer, Inc.
9.10.1 Company Overview
9.10.2 Financial Overview
9.10.3 Product Portfolio
9.10.4 Business Strategies
9.10.5 Recent Developments
9.11 Sanofi
9.11.1 Company Overview
9.11.2 Financial Overview
9.11.3 Product Portfolio
9.11.4 Business Strategies
9.11.5 Recent Developments

List of Figures

FIG. 1 Antibacterial Drugs: Market Segmentation
FIG. 2 Global Antibacterial Drugs Market, by Class, 2012 (USD Million)
FIG. 3 Porter’s Five Forces Analysis: Global Antibacterial Drugs Market
FIG. 4 Market Attractiveness Analysis: Global Antibacterial Drugs Market, by Geography (2012)
FIG. 5 Comparative Analysis: Global Antibacterial Drugs Market Revenue, by Class, 2012 & 2019 (Value %)
FIG. 6 Global Aminoglycosides Market Revenue, 2011 – 2019 (USD Million)
FIG. 7 Global ß-Lactams Market Revenue, 2011 – 2019 (USD Million)
FIG. 8 Global Tetracyclines Market Revenue, 2011 – 2019 (USD Million)
FIG. 9 Global Sulfonamides Market Revenue, 2011 – 2019 (USD Million)
FIG. 10 Global Quinolones/Fluoroquinolones Market Revenue, 2011 – 2019 (USD Million)
FIG. 11 Global Macrolides Market Revenue, 2011 – 2019 (USD Million)
FIG. 12 Global Phenicols Market Revenue, 2011 – 2019 (USD Million)
FIG. 13 Global Delafloxacin Market, 2015 – 2019 (USD Million)
FIG. 14 Global Surotomycin Market, 2016 – 2019 (USD Million)
FIG. 15 Global Tedizolid Market, 2015 – 2019 (USD Million)
FIG. 16 Global Ceftolozane/Tazobactam Market, 2015 – 2019 (USD Million)
FIG. 17 Global Dalvance (Dalbavancin) Market, 2015 – 2019 (USD Million)
FIG. 18 Global Eravacycline Market, 2016 – 2019 (USD Million)
FIG. 19 Global Delamanid Market, 2017 – 2019 (USD Million)
FIG. 20 Global CAZ AVI Market, 2015 – 2019 (USD Million)
FIG. 21 Global Solithromycin Market, 2016 – 2019 (USD Million)
FIG. 22 Global MK-3415A Market, 2016 – 2019 (USD Million)
FIG. 23 Global Oritavancin Market, 2015 – 2019 (USD Million)
FIG. 24 Comparative Analysis: Global Antibacterial Drugs Market Revenue, by Geography, 2012 & 2019 (Value %)
FIG. 25 North America Antibacterial Drugs Market Revenue, 2011 – 2019 (USD Million)
FIG. 26 Europe Antibacterial Drugs Market Revenue, 2011 – 2019 (USD Million)
FIG. 27 Asia-Pacific Antibacterial Drugs Market Revenue, 2011 – 2019 (USD Million)
FIG. 28 RoW Antibacterial Drugs Market Revenue, 2011 – 2019 (USD Million)
FIG. 29 Market Share by Key Players: Global Antibacterial Drugs Market, 2012 (%)
FIG. 30 Annual Revenue: AstraZeneca plc, 2010 – 2012 (USD Million)
FIG. 31 Annual Revenue: Bayer AG, 2010 – 2012 (USD Million)
FIG. 32 Annual Revenue: Bristol-Myers Squibb Company 2010 – 2012 (USD Million)
FIG. 33 Annual Revenue: Eli Lilly and Company 2010 – 2012 (USD Million)
FIG. 34 Annual Revenue: Forest Laboratories, Inc., 2010 – 2012 (USD Million)
FIG. 35 Annual Revenue: GlaxoSmithKline plc 2010 – 2012 (USD Million)
FIG. 36 Annual Revenue: Johnson & Johnson 2010 – 2012 (USD Million)
FIG. 37 Annual Revenue: Merck & Co., Inc. 2010 – 2012 (USD Million)
FIG. 38 Annual Revenue: Novartis AG 2010 – 2012 (USD Million)
FIG. 39 Annual Revenue: Pfizer, Inc. 2010 – 2012 (USD Million)
FIG. 40 Annual Revenue: Sanofi, 2010 – 2012 (USD Million)

List of Tables

TABLE 1 Market Snapshot: Global Antibacterial Drugs Market
TABLE 2 Global Antibacterial Drugs Market Revenue, by Class, 2011 – 2019 (USD Million)
TABLE 3 Global Antibacterial Drugs Market Revenue, by Geography, 2011 – 2019 (USD Million)

FEATURED COMPANIES

  • AstraZeneca plc
  • Bayer AG
  • Eli Lilly and Company
  • Forest Laboratories, Inc.
  • GlaxoSmithKline plc
  • Johnson & Johnson
  • MORE

An antibacterial drug is referred to as an agent that interferes with the growth and reproduction of bacteria that cause numerous mild to severe infections in humans. These agents possess bactericidal activity which target various parts of bacterial physiology such as protein synthesis, cell wall synthesis, nucleic acid synthesis and permeability of cell membrane, and therefore help in treating infections. Antibacterial drugs have been utilized by humans since the discovery of first antibacterial in the form of penicillin in 1928 and presently there are a lot of antibacterial drugs available for the treatment of various indications like pneumonia, tuberculosis, tetanus, diphtheria, diarrhea, legionellosis and other diseases.

The global antibacterial drugs market has been categorized into seven segments based on their class, namely, aminoglycosides, ß-lactams, tetracyclines, sulfonamides, quinolones/ fluoroquinolones, macrolides and phenicols. In 2012, ß-lactams class occupied the leading position with a share of 57.1% of the global antibacterial drugs market followed by the quinolones. However, these drug classes are expected to witness decline in their market share during the forecast period due to patent expiry of key branded formulations and growing number of drug resistant bacterial strains.

Hence, on account of the above mentioned factors, the global antibacterial drugs market is expected to witness slow growth during the forecast period 2013 to 2019. However, growing demand for therapies against bacterial infections and rising elderly populations are some of the factors that are anticipated to maintain steady growth of the antibacterial drugs market. Additionally, expected launch of various antibacterial agents that are currently in developmental stages, such as tedizolid (Cubist Pharmaceuticals), Dalvance (Durata Therapeutics), surotomycin (Cubist Pharmaceuticals), MK-3415A (Merck) during the forecast period is also expected to restore growth of this market.

Asia-Pacific held the largest share of the revenue generated by the global antibacterial drugs market in 2012. This region is also expected to experience the highest growth rate during the forecast period 2013 to 2019. The major factors responsible for this region to hold leadership position in this market in 2012 include presence of large number of generic manufacturers in Asian countries, growing incidences of bacterial infections such as MRSA (methicillin resistant Staphylococcus aureus) and C. difficile and increasing purchasing power of the people of this region. Moreover, presence of a large population base and growing elderly population which is more prone to diseases would consequently increase the uptake of antibacterial drugs in the Asian region. North America held the second largest revenue share followed by Europe in the antibacterial drugs market in 2012. Market maturity, shortened product lifecycle, stringent regulatory requirements and generic infiltration are some of the factors that accounted for slow growth of this market.

AstraZeneca plc, Bayer AG, Bristol-Myers Squibb Company, Eli Lilly and Company, Forest Laboratories, Inc., GlaxoSmithKline plc, Johnson & Johnson, Merck & Co., Inc., Novartis AG, Pfizer, Inc., and Sanofi are the major players engaged in the development, production and marketing of various antibacterial drugs. These players have worldwide presence in the pharmaceutical industry and are involved in constant competition with each other. Major customers for their antibacterial drugs include hospitals, private clinics, physicians and patients.

- AstraZeneca plc
- Bayer AG
- Bristol-Myers Squibb Company
- Eli Lilly and Company
- Forest Laboratories, Inc.
- GlaxoSmithKline plc
- Johnson & Johnson
- Merck & Co., Inc.
- Novartis AG
- Pfizer, Inc.
- Sanofi

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos